Effects of thrombolytic drugs and a selective endothelin-1 receptor antagonist on acute pulmonary thromboembolism in dogs

Chinese Medical Journal

Volumn 123, Issue 4, 2010, Pages 395-400

  Han, Li ^a   Li, Qing Yun ^a   Zhou, Ling ^a   Wang, Xi ^a   Bao, Zhi Yao ^a   Li, Min ^a   Wan, Huan Ying ^a   Shi, Guo Chao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute pulmonary thromboembolism; Endothelin 1 receptor antagonist; Pulmonary artery pressure; Thrombolytics

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOG; DRUG EFFECT; HISTOPATHOLOGY; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MONOTHERAPY; NONHUMAN; PROTEIN BLOOD LEVEL;

ANIMALS; DOGS; ENDOTHELIN-1; FIBRINOLYTIC AGENTS; PEPTIDES, CYCLIC; PULMONARY EMBOLISM; RANDOM ALLOCATION; RECEPTOR, ENDOTHELIN A; THROMBOXANES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77149154030     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.04.003     Document Type: Article

References (21)

1. Tan P, Luscinskas FW, Homer-Vanniasinkam S. Cellular and molecular mechanisms of inflammation and thrombosis. Eur J Vasc Endovasc Surg 1999; 17: 373-389.
2. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70: 7-30.
3. Eagleton MJ, Henke PK, Luke CE, Hawley AE, Bedi A, Knipp BS, et al. Inflammation and intimal hyperplasia associated with experimental pulmonary embolism. J Vasc Surg 2002; 36: 581-588.
4. Stratmann G, Gregory GA. Neurogenic and humoral vasoconstriction in acute pulmonary thromboembolism. Anesth Analg 2003; 97: 341-354.
5. Kline JA, Zeitouni R, Marchick MR, Hernandez-Nino J, Rose GA. Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. Am Heart J 2008; 156: 308-314.
6. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177: 1018-1025.
7. Takamori S, Mifune H, Sakamoto H, Hayashi A, Terazaki Y, Miwa K, et al. Vasoactive peptides in a pulmonary embolism model. Surg Today 2002; 32: 707-710.
8. Lee JH, Chun YG, Lee IC, Tuder RM, Hong SB, Shim TS, et al. Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Am J Respir Crit Care Med 2001; 164: 1282-1287.
9. Carlbom DJ, Davidson BL. Pulmonary embolism in the critically ill. Chest 2007; 132: 313-324.
10. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877-905.
11. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48: 23-33.
12. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008; 153: 1105-1119.
13. Lee JH, Kim S, Park BK, Kim WS, Kim DS, Kim WD, et al. The effect of a combination of inhaled nitric oxide and an endothelin A-receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Lung 2005; 183: 139-149.
14. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006; 110: 386-414.
15. Tanus-Santos JE, Gordo WM, Udelsmann A, Moreno H Jr. The hemodynamic effects of endothelin receptor antagonism during a venous air infusion in dogs. Anesth Analg 2000; 90: 102-106.
16. Battistini B, Verreault M, Ayach B, Blouin A, Cernacek P, Jeng AY, et al. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model. J Cardiovasc Pharmacol 2004; 44 (Suppl 1): S386-S389.
17. Ji YQ, Zhang ZH, Zhang P. Thrombosis and its significance after experimental pulmonary thromboembolism. Chin Med J 2003; 116: 49-52.
18. Tsang J, Battistini B, Dussault P, Stewart K, Qayumi KA. Biphasic release of immunoreactive endothelins following acute pulmonary thromboembolism in pigs. J Cardiovasc Pharmacol 2000; 36 (5 Suppl 1): S221-S224.
19. Simon M, Battistini B, Kim YJ, Tsang J. Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. Respir Physiol Neurobiol 2003; 138: 97-106.
20. Sofia M, Faraone S, Alifano M, Micco A, Albisinni R, Maniscalco M, et al. Endothelin abnormalities in patients with pulmonary embolism. Chest 1997; 111: 544-549.
21. Tanus-Santos JE, Gordo WM, Udelsmann A, Cittadino MH, Moreno H Jr. Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs. Chest 2000; 118: 175-179.